Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orantinib in Advanced Hepatocellular Carcinoma
NCT00784290Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2003
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orantinib in hepatocellular carcinoma (HCC), sponsored by Taiho Pharmaceutical Co., Ltd.. Started Sep 2003; status: completed.
02
Drugs
orantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00784290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784290.